CCC
OGN icon

Crescent Capital Consulting’s Organon & Co OGN Stock Holding History

Crescent Capital Consulting’s Portfolio OGN Stock Details OGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		$146K Buy
4,862
+301
+7% +$9.8K 0.02% 201
2021
Q3 		$149K Sell
4,561
-208
-4% -$6.66K 0.03% 201
2021
Q2 		$142K Buy
+4,769
New +$157K 0.03% 204

Other funds holding OGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Crescent Capital Consulting's OGN Position: Q4 2021 in Review

Crescent Capital Consulting increased its Organon & Co (OGN) stake by 6.6% in Q4 2021, buying an estimated $9.8K and bringing the position to 4,862 shares worth $146K. The position accounts for 0.02% of the portfolio, ranked #201.

Crescent Capital Consulting first reported a position in OGN in Q2 2021 and has held it in 3 quarters since. The position peaked at $149K in Q3 2021. 907 funds tracked by Wall St. Rank hold OGN as of Q4 2021.

  • Crescent Capital Consulting held 4,862 shares of Organon & Co worth $146K as of Q4 2021.
  • Crescent Capital Consulting bought 301 Organon & Co shares in Q4 2021, an estimated $9.8K.
  • Organon & Co made up 0.02% of Crescent Capital Consulting's portfolio in Q4 2021, its #201 holding.
  • Crescent Capital Consulting first reported a position in Organon & Co in Q2 2021 and has held it in 3 quarters since.
  • Crescent Capital Consulting's Organon & Co position peaked at $149K in Q3 2021.
  • 907 funds tracked by Wall St. Rank held Organon & Co as of Q4 2021.

Based on Crescent Capital Consulting's 13F filing for Q4 2021, filed 18 Jan 2022.